1 |
M. Uguccioni, M. D'Apuzzo, M. Loetscher, B. Dewald, and M. Baggiolini, "Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes", Eur. J. Immunol., Vol. 25, pp. 64-68, 1995.
DOI
|
2 |
R. W. Chapman, J. E. Phillips, R. W. Hipkin, A. K. Curran, D. Lundell, and J. S. Fine, "CXCR2 antagonists for the treatment of pulmonary disease", Pharmacol. Therapeut., Vol. 212, pp. 55-68, 2009.
|
3 |
J. Reutershan, A. Basit, E. V. Galkina, and K. Ley, "Sequential recruitment of neutrophils into lung and bronchoalveolar lavage fluid in LPS-induced lung injury", Am. J. Physiol-Lung C., Vol. 289, pp. L807-L815, 2005.
DOI
|
4 |
S. L. Traves, S. J. Smith, P. J. Barnes, and L. E. Donnelly, "Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2", J. Leukocyte. Biol., Vol. 76, pp. 441-450, 2004.
DOI
|
5 |
K. J.Eash, A. M. Greenbaum, P. K. Gopalan, and D. C. Link, "CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow", J. Clin. Invest., Vol. 120, pp. 2423-2431, 2010.
DOI
|
6 |
R. A. Pauwels and K. F. Rabe, "Burden and clinical features of chronic obstructive pulmonary disease (COPD)", Lancet, Vol. 364, pp. 613-620, 2004.
DOI
|
7 |
E. H. Bel, A. Sousa, L. Fleming, A. Bush, K. F Chung, J. Versnel, A. H. Wagener, S. S. Wagers, P. J. Sterk, and C. H. Compton, "Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI)", Thorax, 2010.
|
8 |
P. Anderson, "Emerging therapies in cystic fibrosis", Ther. Adv. Respir. Dis., Vol. 4, pp. 177-185, 2010.
DOI
|
9 |
P. M. Murphy, "Neutrophil receptors for interleukin-8 and related CXC chemokines", Semin. Hematol., Vol. 34, pp. 311-318, 1997.
|
10 |
W. Sippl, "3D-QSAR - Applications, recent advances, and limitations", in Recent Advances in QSAR Studies: Methods and Applications, Heidelberg: Springer, 2010
|
11 |
B. Sathya and M. Thirumurthy, "Pharmacophore based comparative molecular field analysis of CRTh2 antagonists", J. Chosun Natural Sci., Vol. 8, pp. 89-98, 2015.
DOI
|
12 |
B. Sathya and M. Thirumurthy, "Comparative molecular field analysis of caspase-3 inhibitors", J. Chosun Natural Sci., Vol. 7, pp. 166-172, 2014.
DOI
|
13 |
M. Thirumurthy, "Modeling aided lead design of FAK inhibitors", J. Chosun Natural Sci., Vol. 4, pp. 266-272, 2011.
|
14 |
M. Thirumurthy, "3D-QSAR studies of 3,5-disubstituted quinolines inhibitors of c-Jun N-terminal kinase-3", J. Chosun Natural Sci., Vol. 4, pp. 216-221, 2011.
|
15 |
D. W. Porter , M. Bradley, Z. Brown, S. J. Charlton, B. Cox, P. Hunt, D. Janus, S. Lewis, P. Oakley, D. O'Connor, J. Reilly, N. Smith, and N. J. Press, "The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists", Bioorg. Med. Chem. Lett., Vol. 24, pp. 3285-3290, 2014.
DOI
|
16 |
SYBYL Software, Version X 2.0., 2006, Tripos Associates Inc, St. Louis, USA.
|
17 |
G. Klebe, U. Abraham, and T. Mietzner, "Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity", J. Med. Chem., Vol. 37, pp. 4130-4146, 1994.
DOI
|
18 |
S. Wold, A. Ruhe, H. Wold, and W. J. Dunn, "The collinearity problem in linear-regression- the partial least squares (PLS) approach to generalized inverses", SIAM Journal on Scientific and Statistical Computing, Vol. 5, pp. 735-743, 1984.
DOI
|
19 |
S. Wold, "Cross-validatory estimation of the number of components in factor and principal component model", Technometrics, Vol. 20, pp. 397-405, 1978.
DOI
|